Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 2016

View Archived Issues

Kezar Life Sciences begins phase I study of its immunoproteasome inhibitor

Aphios obtains funding from NIAID to develop cure for HIV/AIDS

C3 may be useful as a biomarker to monitor ERT efficacy in Fabry disease

New transgenic model to assess target engagement of tau gene silencing therapies in live mice

Phase I data for CAR-modified T-cell immunotherapy in patients with non-Hodgkin's lymphoma

Azevan reports promising phase II data for SRX-246 in intermittent explosive disorder

Merck KGaA joins project to improve vaccine purification processes

FDA approves Shire's Cuvitru for primary immunodeficiency

Allele Biotechnology and Pharmaceuticals awarded SBIR grant from NHLBI

Neural Analytics receives NIH grant to develop brain diagnostic and monitoring platform

Launch of Relay Therapeutics with novel drug discovery platform focused on protein motion

Bayer and Monsanto sign definitive merger agreement

Aerie reports encouraging data from first registration trial of Roclatan

Allergan to acquire Vitae Pharmaceuticals and strengthen its dermatology product pipeline

Inhibikase Therapeutics cleared to conduct clinical studies of ABL inhibitors in Parkinson's disease

SELLAS Life Sciences enters CRADA to develop AML-MRD assay

Lenvatinib approved in E.U. for renal cell carcinoma

New gene silencing model confirms the XPO1 gene as a target for treating heart failure

KCa3.1 channel blockade shows promise as a therapeutic target in pulmonary fibrosis

FDA committee says studies of apaziquone do not show evidence of treatment effect

Bexion initiates phase I trial of BXQ-350 for advanced solid tumors

Basilea partners with Asahi Kasei Pharma for isavuconazole in Japan

Research indicates AQP1 as potential therapeutic target for pulmonary hypertension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...